Global Information Inc. would like to present a new market research report, "Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets" by BCC Research.
According to the new report, the value of the market for ubiquitin proteasome drugs was an estimated $1.4 billion in 2009, but is expected to increase to $3 billion in 2015, for a 6-year compound annual growth rate (CAGR) of 13.5%.
The value of the only approved drug on the market, Velcade, is projected to increase at a CAGR of 13.5% to $1 billion in the United States in 2015, after being valued at $468 million in the U.S. in 2009.
On the global market, Velcade was valued at $933 million in 2009 and sales are expected to increase at a 6-year CAGR of 13.6% to reach $2 billion in 2015.
Velcade, Millennium Pharmaceuticals primary source of revenue (more than 45% of its annual sales), is a therapeutic treatment for patients with multiple myeloma, a type of bone marrow cancer that can damage a patients immune system. Although Velcade faced some competition from other drug alternatives such as Revlimid, it still holds 40% of the multiple myeloma market.
More importantly, recent developments in the field of proteasome inhibitors bring new perspective and alternatives that may change the current market. This report presents new venues in this area of drug development as well as new competitors and possibly a new outlook for this area of drug discovery in the next couple of years.
The report identifies two major research trends in UPS: proteasome inhibitors versus ubiquitination reaction components as drug targets. This study describes current products in each area, identifies current market participants and, most importantly, notes the trends that are going to affect further drug development in this area. The report also provides information about less-developed areas of UPS, and gives a list of current companies that have new UPS-related products in development.